Bio Pharma Dive
FEBRUARY 20, 2024
The biotech set a price of roughly $515,000 per patient for its therapy Amtagvi, the first to be approved based on a decades-old technique of using tumor-infiltrating lymphocytes.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 20, 2024
The Indian Institute of Science (IISc) and Blockchain For Impact (BFI) have teamed up to maximise translational research projects where the latter aims to allocate US$1 million. The collaboration, under the BFI-Biome Virtual Network Programme, will see BFI to support various research projects at the IISc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 20, 2024
Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 20, 2024
Neuroscientists have ‘hacked’ the brain’s memory pathways with a new prosthetic system that could help improve the recollection of specific memories.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
FEBRUARY 20, 2024
Rapt reported one case of liver failure in a study participant who received the biotech’s drug, which is seen by analysts as a possible competitor to Dupixent.
Pharmaceutical Technology
FEBRUARY 20, 2024
Following FDA orphan designation in 2023, the company is eligible for market exclusivity in mesothelioma for both regions.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
FEBRUARY 20, 2024
We explore the challenges when conducting analytical testing of the popular preservative Benzalkonium Chloride.
Bio Pharma Dive
FEBRUARY 20, 2024
Can asynchronous advisory programs can add distinct value to your strategic mix? Yes! Here's how.
Pharmaceutical Technology
FEBRUARY 20, 2024
The Singapore HSA has accepted the new drug application (NDA) for AffaMed Therapeutics’ DEXTENZA to treat ocular inflammation and pain.
Bio Pharma Dive
FEBRUARY 20, 2024
A “second request” from the Federal Trade Commission could protract the timing of AbbVie’s proposed acquisition, which is slated to close around the middle of the year.
Pharmaceutical Technology
FEBRUARY 20, 2024
The US FDA has accepted for priority review argenx's sBLA for VYVGART Hytrulo to treat chronic inflammatory demyelinating polyneuropathy.
Bio Pharma Dive
FEBRUARY 20, 2024
The veteran executive, who guided AbbVie through its separation from Abbott Laboratories, will be succeeded by Chief Operating Officer Robert Michael.
Pharmaceutical Technology
FEBRUARY 20, 2024
Pfizer has obtained marketing authorisation from the European Commission (EC) for VELSIPITY to treat ulcerative colitis (UC).
Fierce Pharma
FEBRUARY 20, 2024
After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its quest to dominate the red-hot antibody-drug conjugate (ADC) field. | Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08 billion) into an expansion of its production facility in Pfaffenhofen an der Ilm, Germany.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
FEBRUARY 20, 2024
AstraZeneca has concluded the acquisition of clinical-stage biopharmaceutical company Icosavax in a $1.1bn deal.
Bio Pharma Dive
FEBRUARY 20, 2024
The FDA approved the targeted therapy together with chemo for first-line metastatic lung cancer, while fresh trial results supported earlier use.
Pharma Times
FEBRUARY 20, 2024
The nanogels, in combination with rolipram, contributed to the recovery of injured tissue
Fierce Pharma
FEBRUARY 20, 2024
AstraZeneca, having surpassed its long-term $45 billion revenue goal last year, has handsomely rewarded its chief executive. | AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe. Still, as in years past, not everyone is pleased with Soriot’s 2023 windfall.
pharmaphorum
FEBRUARY 20, 2024
The FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in rare autoimmune disease chronic inflammatory demyelinating polyneuropathy (CIDP).
Fierce Pharma
FEBRUARY 20, 2024
Since he took over as CEO at Bayer nine months ago, Bill Anderson had had to make tough decisions to try to get the floundering conglomerate back on track. | Bayer plans to cut its investor dividends to help reduce the company’s debt. Over three years, Bayer intends to pay out the legal minimum. For 2023, that comes to €0.11 per share compared to the €2.40 the company paid out per share in 2022.
pharmaphorum
FEBRUARY 20, 2024
The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s first-to-market Zeposia.
Fierce Pharma
FEBRUARY 20, 2024
On AbbVie’s latest earnings call, analysts were curious whether long-time CEO Richard Gonzalez was weighing a succession plan now that Humira’s loss of U.S. exclusivity has passed. | Robert Michael, AbbVie’s current president and chief operating officer, has been tapped by the company’s board of directors to take over Richard Gonzalez’s CEO post on July 1.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
FEBRUARY 20, 2024
Bayer takes anti-alpha2 antiplasmin antibody BAY3018250 into phase 2 as a deep vein thrombosis treatment, hoping to improve on thrombolytics.
Pharma Times
FEBRUARY 20, 2024
The new programme will engage with children and young people under the age of 18 years
pharmaphorum
FEBRUARY 20, 2024
Google DeepMind and Owkin scientists have joined forces to create Bioptimus, an AI startup that aims to develop a foundation model for biology
Outsourcing Pharma
FEBRUARY 20, 2024
Some forms of depression cannot be cured by current treatments including antidepressants or going to psychological counselling or psychotherapy.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
FEBRUARY 20, 2024
Patient feedback is driving innovation in next-generation drug delivery devices, improving patient adherence and experience. Learn how these advancements are shaping the future of healthcare.
Pharmaceutical Commerce
FEBRUARY 20, 2024
The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.
pharmaphorum
FEBRUARY 20, 2024
Learn about the transparency of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) regarding medicines pricing and the Association of the British Pharmaceutical Industry (ABPI). Explore how these factors impact the pharmaceutical industry.
Rethinking Clinical Trials
FEBRUARY 20, 2024
Speaker Jeffrey Carson, MD, MACP Principal Investigator and Study Chair MINT Trial Provost-New Brunswick, Rutgers Biomedical Health Sciences Distinguished Professor of Medicine Richard C. Reynolds, M.D. Chair in General Internal Medicine Rutgers, Robert Wood Johnson Medical School Keywords Transfusion; MI; MINT; Anemia; Clinical trials Key Points Anemia is common in patients with acute MI.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
304 
Let's personalize your content